Art. -Nr.: HY-103297

Copy Link Print Information

OXFBD02

Kundenbewertung

Based on 1 Customer Validation

OXF BD 02 is a selective inhibitor of BRD4(1) (the first bromodomain of BRD4) with IC₅₀ value of 382 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.04%
CAS. Nr.: 1429129-68-9
Formel: C₁₈H₁₇NO₃
Molecular Weight:295.33

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

OXFBD02 Chemical Structure

CAS. Nr.: 1429129-68-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

OXF BD 02 is a selective inhibitor of BRD4(1) (the first bromodomain of BRD4) with IC₅₀ value of 382 nM^[1].

IC₅₀ & Target

BRD4(1)

382 nM (IC₅₀)

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	27.1 μM Compound: 1a; OXFBD02	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
A498	GI₅₀	1.58 μM Compound: 1a; OXFBD02	Growth inhibition of human A498 cells after 48 hrs by SRB assay Growth inhibition of human A498 cells after 48 hrs by SRB assay	[PMID: 29776834]
A549	GI₅₀	22.4 μM Compound: 1a; OXFBD02	Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
A549	IC₅₀	>10 μM Compound: 8	Cytotoxicity against human A549 cells after 72 hrs by MTS assay Cytotoxicity against human A549 cells after 72 hrs by MTS assay	[PMID: 23517011]
ACHN	GI₅₀	4.76 μM Compound: 1a; OXFBD02	Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
BT-549	GI₅₀	28.2 μM Compound: 1a; OXFBD02	Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
CAKI-1	GI₅₀	4.58 μM Compound: 1a; OXFBD02	Growth inhibition of human CAKI-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human CAKI-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
CCRF-CEM	GI₅₀	14.8 μM Compound: 1a; OXFBD02	Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
COLO 205	GI₅₀	5.25 μM Compound: 1a; OXFBD02	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
DU-145	GI₅₀	6.95 μM Compound: 1a; OXFBD02	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HCC 2998	GI₅₀	8.55 μM Compound: 1a; OXFBD02	Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HCT-116	GI₅₀	7.08 μM Compound: 1a; OXFBD02	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HCT-15	GI₅₀	3.52 μM Compound: 1a; OXFBD02	Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HeLa	IC₅₀	>100 μM Compound: 8	Cytotoxicity against human HeLa cells after 24 hrs by WST-1 assay Cytotoxicity against human HeLa cells after 24 hrs by WST-1 assay	[PMID: 23517011]
HL-60(TB)	GI₅₀	2.17 μM Compound: 1a; OXFBD02	Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HOP-62	GI₅₀	4.89 μM Compound: 1a; OXFBD02	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HOP-92	GI₅₀	1.02 μM Compound: 1a; OXFBD02	Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
Hs-578T	GI₅₀	1.93 μM Compound: 1a; OXFBD02	Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
HT-29	GI₅₀	4.54 μM Compound: 1a; OXFBD02	Growth inhibition of human HT-29 cells after 48 hrs by SRB assay Growth inhibition of human HT-29 cells after 48 hrs by SRB assay	[PMID: 29776834]
IGROV-1	GI₅₀	23.2 μM Compound: 1a; OXFBD02	Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
K562	GI₅₀	8.69 μM Compound: 1a; OXFBD02	Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
KM12	GI₅₀	8.2 μM Compound: 1a; OXFBD02	Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
LOX IMVI	GI₅₀	3.6 μM Compound: 1a; OXFBD02	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
M14	GI₅₀	4.48 μM Compound: 1a; OXFBD02	Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
Malme-3M	GI₅₀	28.9 μM Compound: 1a; OXFBD02	Growth inhibition of human MALME-3M cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MALME-3M cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MCF7	GI₅₀	1.25 μM Compound: 1a; OXFBD02	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 29776834]
MDA-MB-231	GI₅₀	3.92 μM Compound: 1a; OXFBD02	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MDA-MB-435	GI₅₀	3.48 μM Compound: 1a; OXFBD02	Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MDA-MB-468	GI₅₀	1.89 μM Compound: 1a; OXFBD02	Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MOLT-4	GI₅₀	17.9 μM Compound: 1a; OXFBD02	Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
MV4-11	IC₅₀	0.794 μM Compound: 8	Cytotoxicity against human MV4-11 cells after 72 hrs by MTS assay Cytotoxicity against human MV4-11 cells after 72 hrs by MTS assay	[PMID: 23517011]
NCI/ADR-RES	GI₅₀	6.32 μM Compound: 1a; OXFBD02	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H1975	IC₅₀	>10 μM Compound: 8	Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTS assay	[PMID: 23517011]
NCI-H226	GI₅₀	21.3 μM Compound: 1a; OXFBD02	Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H322M	GI₅₀	8.41 μM Compound: 1a; OXFBD02	Growth inhibition of human NCI-H322M cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H460	GI₅₀	25.1 μM Compound: 1a; OXFBD02	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
NCI-H522	GI₅₀	27 μM Compound: 1a; OXFBD02	Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-3	GI₅₀	6.64 μM Compound: 1a; OXFBD02	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-4	GI₅₀	6.35 μM Compound: 1a; OXFBD02	Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-5	GI₅₀	31.8 μM Compound: 1a; OXFBD02	Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
OVCAR-8	GI₅₀	8.33 μM Compound: 1a; OXFBD02	Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
RPMI-8226	GI₅₀	1.94 μM Compound: 1a; OXFBD02	Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
RXF 393	GI₅₀	17.2 μM Compound: 1a; OXFBD02	Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SF-268	GI₅₀	39.3 μM Compound: 1a; OXFBD02	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SF-295	GI₅₀	7.31 μM Compound: 1a; OXFBD02	Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SF-539	GI₅₀	4.56 μM Compound: 1a; OXFBD02	Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-MEL-2	GI₅₀	23.5 μM Compound: 1a; OXFBD02	Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-MEL-28	GI₅₀	9.15 μM Compound: 1a; OXFBD02	Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-MEL-5	GI₅₀	5.95 μM Compound: 1a; OXFBD02	Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SK-OV-3	GI₅₀	7.01 μM Compound: 1a; OXFBD02	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SN12C	GI₅₀	3.99 μM Compound: 1a; OXFBD02	Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SNB-19	GI₅₀	5.69 μM Compound: 1a; OXFBD02	Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SNB-75	GI₅₀	0.423 μM Compound: 1a; OXFBD02	Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SR	GI₅₀	1.01 μM Compound: 1a; OXFBD02	Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
SW-620	GI₅₀	24.5 μM Compound: 1a; OXFBD02	Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
T47D	GI₅₀	7.7 μM Compound: 1a; OXFBD02	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
TK-10	GI₅₀	1.08 μM Compound: 1a; OXFBD02	Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
U-251	GI₅₀	15 μM Compound: 1a; OXFBD02	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
U2OS	IC₅₀	>100 μM Compound: 8	Cytotoxicity against human U2OS cells after 24 hrs by WST-1 assay Cytotoxicity against human U2OS cells after 24 hrs by WST-1 assay	[PMID: 23517011]
UACC-257	GI₅₀	4.66 μM Compound: 1a; OXFBD02	Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]
UO-31	GI₅₀	4.58 μM Compound: 1a; OXFBD02	Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay	[PMID: 29776834]

Chemical Information

CAS. Nr. 1429129-68-9
Appearance Solid
Molecular Weight 295.33
Formel C₁₈H₁₇NO₃
Color White to off-white
SMILES

OC(C1=CC=CC=C1)C2=CC(O)=CC(C3=C(C)ON=C3C)=C2
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (338.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3860 mL

16.9302 mL

33.8604 mL

5 mM

0.6772 mL

3.3860 mL

6.7721 mL

10 mM

0.3386 mL

1.6930 mL

3.3860 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hewings DS, et al. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem. 2013 Apr 25;56(8):3217-27. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3860 mL	16.9302 mL	33.8604 mL	84.6511 mL
	5 mM	0.6772 mL	3.3860 mL	6.7721 mL	16.9302 mL
	10 mM	0.3386 mL	1.6930 mL	3.3860 mL	8.4651 mL
	15 mM	0.2257 mL	1.1287 mL	2.2574 mL	5.6434 mL
	20 mM	0.1693 mL	0.8465 mL	1.6930 mL	4.2326 mL
	25 mM	0.1354 mL	0.6772 mL	1.3544 mL	3.3860 mL
	30 mM	0.1129 mL	0.5643 mL	1.1287 mL	2.8217 mL
	40 mM	0.0847 mL	0.4233 mL	0.8465 mL	2.1163 mL
	50 mM	0.0677 mL	0.3386 mL	0.6772 mL	1.6930 mL
	60 mM	0.0564 mL	0.2822 mL	0.5643 mL	1.4109 mL
	80 mM	0.0423 mL	0.2116 mL	0.4233 mL	1.0581 mL
	100 mM	0.0339 mL	0.1693 mL	0.3386 mL	0.8465 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

OXFBD02

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

OXFBD02

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

OXFBD02 Related Classifications

HY-103297 Related Classifications